Foundry Partners LLC Acquires Shares of 73,901 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Foundry Partners LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 73,901 shares of the medical equipment provider's stock, valued at approximately $4,582,000. Foundry Partners LLC owned about 0.11% of Lantheus as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tucker Asset Management LLC raised its holdings in shares of Lantheus by 239.0% during the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 282 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider's stock valued at $32,000 after acquiring an additional 225 shares in the last quarter. Covestor Ltd raised its holdings in shares of Lantheus by 62.7% during the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 203 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Lantheus by 36.6% during the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider's stock valued at $40,000 after acquiring an additional 156 shares in the last quarter. Finally, NBC Securities Inc. bought a new position in Lantheus in the third quarter worth $46,000. Institutional investors own 99.06% of the company's stock.

Insider Activity at Lantheus

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company's stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company's stock, valued at approximately $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company's stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company's stock, valued at approximately $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The disclosure for this sale can be found here. Insiders have sold 94,545 shares of company stock valued at $6,169,936 over the last ninety days. Insiders own 2.10% of the company's stock.

Lantheus Stock Down 1.2 %

Shares of NASDAQ LNTH traded down $0.74 during trading on Monday, reaching $63.07. The company had a trading volume of 652,013 shares, compared to its average volume of 1,053,747. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $100.85. The stock has a market cap of $4.32 billion, a PE ratio of 13.59 and a beta of 0.54. The business's 50-day moving average is $60.94 and its 200 day moving average is $62.78. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts' consensus estimates of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The firm had revenue of $354.00 million for the quarter, compared to analysts' expectations of $350.44 million. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on LNTH shares. JMP Securities reiterated a "market outperform" rating and issued a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. B. Riley increased their price objective on Lantheus from $95.00 to $99.00 and gave the stock a "buy" rating in a report on Thursday. StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Saturday, January 13th. Finally, Truist Financial reiterated a "buy" rating and issued a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a report on Monday, February 26th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average price target of $104.71.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.